Personal tools

Sponsorname

Your company could advertise here

www.fla-consulting.eu

Reference:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023 Article 63 Paragraph 3 – 5: Difference between revisions

From GxPlex

Jump to: navigation, search
m 1 revision imported
m 1 revision imported
 
(5 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{#set:
{{ReferenceData
|HasDocument=Document:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023
|has_document=Document:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023
|RefScope=MD
|module=3
|RefDocPart=Article 63
|unit=3.1.1
|scope=MD
|doc_part=Article 63
Paragraph 3 – 5
Paragraph 3 – 5
|RefLanguage=EN
|language=EN
|RefTagsEN=
|entry_by=Florian Adragna
|RefTagsOriginal=
|contributors=
|RefTagsFR=
|tags=TAG-00031-Pat-onA ++ TAG-00029-Inf-rte ++ TAG-00028-Leg-ich ++ TAG-00155-Med-Med
}}
|tags_display=[[Glossary:TAG-00031-Pat-onA|Patient information sheet]], [[Glossary:TAG-00029-Inf-rte|Informed consent]], [[Glossary:TAG-00028-Leg-ich|Legal representative]], [[Glossary:TAG-00155-Med-Med|Medical device]]
 
|comment=Written format requirement for subject information (device)
{{:Document:EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023}}
|content=3.  The information referred to in paragraph 2 shall be prepared in writing and be available to the subject or, where the subject is not able to give informed consent, his or her legally designated representative.
 
{| class="gplx-infobox"
|-
! colspan="2" class="gplx-infobox-header" | Reference Details
|-
! Scope
| MD
|-
! Document part
| Article 63
Paragraph 3 – 5
|-
! Language
| EN
|-
! Original entry by
| Florian Adragna
|-
! Contributors
|
|-
! Tags (EN)
|
|-
! Tags (original language)
|
|-
! Tags (FR)
|  
|-
! Comment
| Written format requirement for subject information (device)
|}
 
== Content ==
3.  The information referred to in paragraph 2 shall be prepared in writing and be available to the subject or, where the subject is not able to give informed consent, his or her legally designated representative.


4.  In the interview referred to in point (c) of paragraph 2, special attention shall be paid to the information needs of specific patient populations and of individual subjects, as well as to the methods used to give the information.
4.  In the interview referred to in point (c) of paragraph 2, special attention shall be paid to the information needs of specific patient populations and of individual subjects, as well as to the methods used to give the information.


5.  In the interview referred to in point (c) of paragraph 2, it shall be verified that the subject has understood the information.
5.  In the interview referred to in point (c) of paragraph 2, it shall be verified that the subject has understood the information.
}}

Latest revision as of 13:49, 16 July 2026



Document information
Reference EU Regulation (EU) 2017/745 - Medical Device Regulation 20-Mar-2023
Validity area EU
Scope(s) MD
Document name Regulation (EU) 2017/745 - Medical Device Regulation
Version / Revision 20-Mar-2023
Status Current
Document type Legal act
Language(s) EN
Description REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC
Official source Official link
Restricted access No
Submitted by Florian Adragna
Contributors


Reference Details
Module Module 3 — Unit 3.1.1
Scope MD
Document part Article 63

Paragraph 3 – 5

Language EN
Original entry by Florian Adragna
Contributors
Tags Patient information sheet, Informed consent, Legal representative, Medical device

Content

3. The information referred to in paragraph 2 shall be prepared in writing and be available to the subject or, where the subject is not able to give informed consent, his or her legally designated representative.

4. In the interview referred to in point (c) of paragraph 2, special attention shall be paid to the information needs of specific patient populations and of individual subjects, as well as to the methods used to give the information.

5. In the interview referred to in point (c) of paragraph 2, it shall be verified that the subject has understood the information.